Poolbeg Pharma Résultats passés

Passé contrôle des critères 0/6

Poolbeg Pharma has been growing earnings at an average annual rate of 10.5%, while the Pharmaceuticals industry saw earnings declining at 5.2% annually.

Informations clés

10.5%

Taux de croissance des bénéfices

10.5%

Taux de croissance du BPA

Pharmaceuticals Croissance de l'industrie	14.1%
Taux de croissance des recettes	n/a
Rendement des fonds propres	-35.2%
Marge nette	n/a
Dernière mise à jour des bénéfices	30 Jun 2024

Mises à jour récentes des performances passées

Recent updates

Here's Why We're Not Too Worried About Poolbeg Pharma's (LON:POLB) Cash Burn Situation

Jul 12

Ventilation des recettes et des dépenses

Comment Poolbeg Pharma gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.

Historique des gains et des recettes

AIM:POLB Recettes, dépenses et bénéfices (GBP Millions )
Date	Les revenus	Dépenses G+A	Dépenses de R&D
30 Jun 24	-4	4	2
31 Mar 24	-4	4	2
31 Dec 23	-4	3	2
30 Sep 23	-4	3	2
30 Jun 23	-5	3	2
31 Mar 23	-5	3	2
31 Dec 22	-5	3	2

Des revenus de qualité: POLB is currently unprofitable.

Augmentation de la marge bénéficiaire: POLB is currently unprofitable.

Analyse des flux de trésorerie disponibles par rapport aux bénéfices

Analyse de la croissance passée des bénéfices

Tendance des revenus: Insufficient data to determine if POLB's year-on-year earnings growth rate was positive over the past 5 years.

Accélération de la croissance: Unable to compare POLB's earnings growth over the past year to its 5-year average as it is currently unprofitable

Bénéfices par rapport au secteur d'activité: POLB is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (4.5%).

Rendement des fonds propres

ROE élevé: POLB has a negative Return on Equity (-35.17%), as it is currently unprofitable.

Poolbeg Pharma Résultats passés

Passé contrôle des critères 0/6

Informations clés

Mises à jour récentes des performances passées

Poolbeg Pharma PLC to Report First Half, 2022 Results on Sep 06, 2022

Poolbeg Pharma PLC to Report Q4, 2021 Results on Mar 03, 2022

Recent updates

Companies Like Poolbeg Pharma (LON:POLB) Are In A Position To Invest In Growth

Poolbeg Pharma Announces Voluntary Delist from OTCQB Market

Poolbeg Pharma PLC, Annual General Meeting, Jun 13, 2024

Poolbeg Pharma PLC Receives the Fully Granted Patent from the U.S. Patent Office for Its Immunomodulator II Patent Application

New minor risk - Financial data availability

Executive Chairman of The Board recently bought UK£97k worth of stock

We're Hopeful That Poolbeg Pharma (LON:POLB) Will Use Its Cash Wisely

Poolbeg Pharma plc Appoints Cathal Friel as Executive Chairman

Independent Research Confirms >$10 Billion Market Opportunity for POLB 001 as A Preventative Therapy for Cancer Immunotherapy-Induced Cytokine Release Syndrome (CRS)

Poolbeg Pharma plc Further Data Confirms Polb 001'S Potential in Cancer Immunotherapy-Induced Cytokine Release Syndrome

High number of new and inexperienced directors

Poolbeg Pharma plc Announces Positive Outputs from Lab-Based Analysis of RSV Drug Candidates Identified Using AI RSV Drug Candidates with the High Probability of Successful Successful Successfully

Poolbeg Pharma plc Announces Key Insights from Its Poster Presentation at ASH POLB 001

Poolbeg Pharma plc Announces Directorate Changes

Poolbeg Pharma plc Announces Executive Appointments

Poolbeg Pharma plc Announces Scientific Advisory Board Endorses Influenza Drug Targets Identified in Ai Drug Discovery Programme

We're Hopeful That Poolbeg Pharma (LON:POLB) Will Use Its Cash Wisely

Poolbeg Pharma PLC Announces Favourable Conclusion of Patent Opposition

Poolbeg Pharma Receives Notice of Allowance from the Japanese Patent Office in Relation to its Immunomodulator I Patent Application

Poolbeg Pharma plc Announces Immunomodulator I Patent Opposition Withdrawal

New minor risk - Share price stability

Poolbeg Pharma plc Announces Significant Breakthrough in Its World First Influenza Artificial Intelligence Programme with Cytoreason

Less than half of directors are independent

We're Hopeful That Poolbeg Pharma (LON:POLB) Will Use Its Cash Wisely

Poolbeg Pharma PLC Announces Board Changes

Poolbeg Pharma plc Announces Strategic Expansion of Polb 001 into Oncology

Poolbeg Pharma PLC Announces Positive Initial Data Analysis in POLB 001 Trial

Poolbeg Pharma Identifies Novel RSV Drug Candidates

Poolbeg Pharma plc Announces POLB 001 LPS Human Challenge Clinical Trial Successfully Completed

Poolbeg Pharma Announces Completion of Influenza AI Model Build

Poolbeg Pharma PLC to Report First Half, 2022 Results on Sep 06, 2022

Poolbeg Pharma plc Receives Ethics and Competent Authority Approval to Commence Its Lipopolysaccharide (Lps) Human Challenge Clinical Trial for Polb 00

Here's Why We're Not Too Worried About Poolbeg Pharma's (LON:POLB) Cash Burn Situation

Poolbeg Pharma plc Provides Project Update for AI Model of RSV Data

Poolbeg Pharma PLC Provides Update on POLB 001 Clinical Development

No independent directors

Poolbeg Pharma plc Provides an Update on the Strengthening of Its Intellectual Property for Its Asset POLB 002

Poolbeg Pharma PLC to Report Q4, 2021 Results on Mar 03, 2022

Poolbeg Pharma PLC has completed an IPO in the amount of £25 million.

Ventilation des recettes et des dépenses

Historique des gains et des recettes

Analyse des flux de trésorerie disponibles par rapport aux bénéfices

Analyse de la croissance passée des bénéfices

Rendement des fonds propres

Rendement des actifs

Rendement des capitaux employés

Découvrir des entreprises performantes dans le passé